What is Bionano Genomics?
Bionano Genomics provides advanced genome analysis software designed to empower genomics laboratories. Their solutions facilitate the analysis and interpretation of data, generating informative visualizations for streamlined reporting of causal variants. The company's offerings include the Saphyr system, a comprehensive sample-to-result solution for structural variation analysis via optical genome mapping, alongside the Saphyr instrument, a single-molecule imager, and proprietary Saphyr Chip consumables. Bionano also offers a suite of Bionano Prep Kits and DNA labeling kits for DNA extraction and labeling. Complementing their hardware, Bionano provides Saphyr and Bionano compute servers and VIA software, a unified system for analyzing genomic variants from microarray and next-generation sequencing data. Their laboratory services extend to diagnostic testing, including FirstStepDx PLUS for autism spectrum disorder and developmental delay, Fragile X syndrome testing, NextStepDx PLUS for exome sequencing, and various OGM-Dx tests for hematological, FSHD, and whole-genome SV analysis in postnatal and prenatal contexts. Founded in 2003 and headquartered in San Diego, California, Bionano Genomics is at the forefront of advancing genomic understanding.
How much funding has Bionano Genomics raised?
Bionano Genomics has raised a total of $107.3M across 7 funding rounds:
Series A
$5.1M
Debt
$782K
Series B
$33.3M
Debt
$5M
Stock Offering
$20.6M
Unspecified
$41.5M
Debt
$1M
Series A (2008): $5.1M with participation from KT Venture Group and Battelle Ventures
Debt (2010): $782K, investors not publicly disclosed
Series B (2012): $33.3M supported by Domain Associates, KT Venture Group, Innovation Valley Partners, Gund Investment Corporation, and Battelle Ventures
Debt (2014): $5M, investors not publicly disclosed
Stock Issuance/Offering (2018): $20.6M, investors not publicly disclosed
Unspecified (2019): $41.5M with participation from East West Bank, Innovatus Capital Partners, and Aspire Capital Fund
Debt (2020): $1M led by PPP
Key Investors in Bionano Genomics
Battelle Ventures
Battelle Ventures is an investment arm of Battelle Memorial Institute, a global research and development organization. They focus on advancing scientific and technological solutions in critical areas, likely bringing a deep understanding of scientific innovation to their investments.
KT Venture Group
KT Venture Group, the investment partner of KLA-Tencor, specializes in the semiconductor equipment sector. Their involvement suggests an interest in the technological underpinnings and manufacturing aspects of Bionano Genomics' solutions.
Domain Associates
Domain Associates is a venture capital firm with a strong specialization in biotech investments, having a significant track record in biopharmaceutical, device, and diagnostic companies. Their participation highlights Bionano Genomics' alignment with the biotech and diagnostics market.
What's next for Bionano Genomics?
The recent major strategic investment in Bionano Genomics, following substantial enterprise-level capital injections, suggests a strategic pivot or an acceleration of its market penetration strategy. This financing is likely to fuel further research and development into its optical genome mapping technology and expand its diagnostic testing services. The company's focus on streamlining complex genomic data analysis positions it to capitalize on the growing demand for personalized medicine and advanced genetic diagnostics. Future endeavors may include expanding its global reach, forging new partnerships within the healthcare and research sectors, and enhancing its software platforms to incorporate emerging genomic analysis techniques. The sustained investor backing indicates a strong belief in Bionano Genomics' long-term vision and its potential to revolutionize the field of genomics.
See full Bionano Genomics company page
